Přejít k obsahu
Merck

Iron chelation in the treatment of cancer: a new role for deferasirox?

Journal of clinical pharmacology (2013-06-07)
Matthew R Bedford, Samuel J Ford, Richard D Horniblow, Tariq H Iqbal, Chris Tselepis
ANOTACE

Iron plays a crucial role in a number of metabolic pathways including oxygen transport, DNA synthesis, and ATP generation. Although insufficient systemic iron can result in physical impairment, excess iron has also been implicated in a number of diseases including ischemic heart disease, diabetes, and cancer. Iron chelators are agents which bind iron and facilitate its excretion. Experimental iron chelators have demonstrated potent anti-neoplastic properties in a number of cancers in vitro. These agents have yet to be translated into clinical practice, however, largely due to the significant side effects encountered in pre-clinical models. A number of licensed chelators, however, are currently in clinical use for the treatment of iron overload associated with certain non-neoplastic diseases. Deferasirox is one such agent and the drug has shown significant anti-tumor effects in a number of in vitro and in vivo studies. Deferasirox is orally administered and has demonstrated a good side effect profile in clinical practice to date. It represents an attractive agent to take forward into clinical trials of iron chelators as anti-cancer agents.

MATERIÁLY
Číslo produktu
Značka
Popis produktu

Sigma-Aldrich
3-Hydroxy-1,2-dimethyl-4(1H)-pyridone, 98%